Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
31/05/2024 | 14:36 | GlobeNewswire Inc. | Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy | NASDAQ:OCGN | Ocugen Inc |
29/05/2024 | 13:15 | GlobeNewswire Inc. | Ocugen to Present at BIO International Convention 2024 | NASDAQ:OCGN | Ocugen Inc |
28/05/2024 | 22:05 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:OCGN | Ocugen Inc |
28/05/2024 | 13:02 | GlobeNewswire Inc. | Ocugen Set to Join Russell 3000® Index Effective June 28, 2024 | NASDAQ:OCGN | Ocugen Inc |
20/05/2024 | 13:00 | GlobeNewswire Inc. | Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024 | NASDAQ:OCGN | Ocugen Inc |
17/05/2024 | 22:30 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:OCGN | Ocugen Inc |
15/05/2024 | 12:30 | GlobeNewswire Inc. | Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy | NASDAQ:OCGN | Ocugen Inc |
14/05/2024 | 21:54 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:OCGN | Ocugen Inc |
14/05/2024 | 14:00 | GlobeNewswire Inc. | Ocugen Provides Business Update with First Quarter 2024 Financial Results | NASDAQ:OCGN | Ocugen Inc |
14/05/2024 | 13:18 | IH Market News | US Futures Remain Steady Amid Wall Street Caution Ahead of April PPI Report | NASDAQ:OCGN | Ocugen Inc |
14/05/2024 | 12:32 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:OCGN | Ocugen Inc |
10/05/2024 | 22:15 | Edgar (US Regulatory) | Form 8-A12G - Registration of securities [Section 12(g)] | NASDAQ:OCGN | Ocugen Inc |
10/05/2024 | 22:05 | GlobeNewswire Inc. | Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock | NASDAQ:OCGN | Ocugen Inc |
10/05/2024 | 13:45 | GlobeNewswire Inc. | Ocugen to Present at May 2024 Investor Conferences | NASDAQ:OCGN | Ocugen Inc |
03/05/2024 | 13:30 | GlobeNewswire Inc. | Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results | NASDAQ:OCGN | Ocugen Inc |
02/05/2024 | 13:15 | GlobeNewswire Inc. | Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress | NASDAQ:OCGN | Ocugen Inc |
29/04/2024 | 12:45 | GlobeNewswire Inc. | Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 | NASDAQ:OCGN | Ocugen Inc |
26/04/2024 | 15:05 | GlobeNewswire Inc. | UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting | NASDAQ:OCGN | Ocugen Inc |
26/04/2024 | 12:30 | GlobeNewswire Inc. | Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting | NASDAQ:OCGN | Ocugen Inc |
19/04/2024 | 13:13 | GlobeNewswire Inc. | Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy | NASDAQ:OCGN | Ocugen Inc |
12/04/2024 | 13:30 | GlobeNewswire Inc. | Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets | NASDAQ:OCGN | Ocugen Inc |
10/04/2024 | 13:02 | GlobeNewswire Inc. | Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication | NASDAQ:OCGN | Ocugen Inc |
08/04/2024 | 12:30 | GlobeNewswire Inc. | Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication | NASDAQ:OCGN | Ocugen Inc |
05/04/2024 | 13:02 | GlobeNewswire Inc. | Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy | NASDAQ:OCGN | Ocugen Inc |
02/04/2024 | 14:00 | GlobeNewswire Inc. | Ocugen Provides Business Update with Certain Financials for the Year Ending 2023 | NASDAQ:OCGN | Ocugen Inc |
02/04/2024 | 00:08 | GlobeNewswire Inc. | Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease | NASDAQ:OCGN | Ocugen Inc |
01/04/2024 | 23:43 | GlobeNewswire Inc. | Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023 | NASDAQ:OCGN | Ocugen Inc |
18/03/2024 | 11:30 | GlobeNewswire Inc. | Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer | NASDAQ:OCGN | Ocugen Inc |
13/03/2024 | 13:00 | GlobeNewswire Inc. | Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 | NASDAQ:OCGN | Ocugen Inc |
06/03/2024 | 13:30 | GlobeNewswire Inc. | Ocugen to Present at Investing in Cures Summit | NASDAQ:OCGN | Ocugen Inc |